Stay updated on SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Sign up to get notified when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    Revision indicator updated to v3.4.2 and the government funding status notice (including the prior Revision: v3.4.1) was removed; no study content changes are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T11:39:23.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Added a notice about a lapse in government funding and that the NIH Clinical Center is open, with status updates linked to opm.gov. Updated the page revision to v3.4.1, replacing v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T10:28:02.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary display option. Updated metadata items include Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0, replacing Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T06:17:42.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The page shows minor date-related updates to Study Record Dates, with new entries for 2026-01-15 and 2025-12-23 and removal of earlier items like Last Update Posted and 2025-06. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-21T04:43:38.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no substantive changes to the study details are evident.
    Difference
    0.0%
    Check dated 2026-01-14T03:07:33.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page adds a Locations section listing study sites in Georgia, Illinois, Massachusetts, North Carolina, and Pennsylvania, and removes the prior state-location entries; the revision tag updates from v3.3.2 to v3.3.3.
    Difference
    0.6%
    Check dated 2025-12-23T21:50:53.000Z thumbnail image

Stay in the know with updates to SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SG + Pembrolizumab in HR+ / HER2- MBC Clinical Trial page.